$ AAPL

$ ABBV

$ ABNB

$ ACGL

$ ADI

$ ADM

$ ADP

$ ADSK

$ AEE

$ AEP

$ AES

$ AFL

$ AIG

$ AIZ

$ AJG

$ AKAM

$ ALB

$ ALGN

$ ALL

$ AMAT

$ AMCR

$ AMD

$ AME

$ AMGN

$ AMP

$ AMT

$ AMZN

$ ANET

$ AOS

$ APA

$ APD

$ APO

$ APTV

$ ARE

$ ATO

$ AVB

$ AWK

$ AXON

$ BA

$ BALL

$ BAX

$ BBY

$ BDX

$ BEN

$ BG

$ BIIB

$ BKNG

$ BLDR

$ BMY

$ BR

$ BRO

$ BXP

$ CAG

$ CAH

$ CARR

$ CAT

$ CBOE

$ CBRE

$ CCL

$ CDNS

$ CDW

$ CEG

$ CF

$ CHD

$ CHRW

$ CI

$ CINF

$ CL

$ CLX

$ CMCSA

$ CMG

$ CMI

$ CMS

$ COIN

$ COO

$ COP

$ COR

$ CPAY

$ CPT

$ CRL

$ CRWD

$ CSCO

$ CTRA

$ CTSH

$ CTVA

$ CVS

$ CVX

$ CZR

$ DAL

$ DASH

$ DAY

$ DD

$ DDOG

$ DE

$ DELL

$ DG

$ DGX

$ DIS

$ DOC

Solventum (SOLV) posted strong Q2 results and raised guidance, with robust adjusted margins and ongoing transformation initiatives positioning the company for long-term margin expansion despite near-term cost pressures.

# Solventum Corporation Delivers Solid Q2 FY2025 Results, Raises Guidance Amid Transformation Progress

---

## Executive Summary

- **Solventum Corporation (SOLV) reported Q2 FY2025 net sales of $2.161B (+3.9% YoY) and adjusted EPS of $1.69 (+8.3% YoY), both meeting or slightly exceeding consensus expectations.** Organic sales growth of 2.8% was driven by volume gains in MedSurg and Health Information Systems, with new product launches and improved commercial execution as key contributors.
- **Earnings quality was strong on an adjusted basis, with adjusted operating margin expanding 120 bps YoY to 21.9%.** However, GAAP operating margin compressed to 9.9% (down 180 bps YoY) due to elevated transformation and ERP costs, higher labor/logistics expenses, and ongoing 3M supply agreement adjustments.
- **Management struck a bullish tone, raising full-year guidance for both organic sales (now 2.0–3.0% growth) and adjusted EPS ($5.80–$5.95).** They highlighted successful execution in core segments and confidence in transformation initiatives, while cautioning about a temporary Q3 dip due to order pull-forward from earlier quarters.
- **Key risks include working capital tightening (cash down to $492M), higher near-term transformation costs, and macro/regulatory uncertainties.** Opportunities center on the P&F divestiture, reduced tariff headwinds, and long-term margin expansion from ERP and separation projects.
- **Catalyst watch:** Near-term, the market will focus on Q3 order normalization and progress on transformation milestones. Longer-term, successful ERP implementation and further margin improvement are key value drivers.

---

## Performance Snapshot

| Metric                | Reported      | Consensus   | Surprise      | YoY Change   |
|-----------------------|--------------|-------------|---------------|-------------|
| Revenue               | $2.161B      | ~$2.15B     | +$11M         | +3.9%       |
| Adjusted EPS          | $1.69        | $1.67       | +$0.02        | +8.3%       |
| Organic Sales Growth  | +2.8%        | ~+2.5%      | +0.3pp        | —           |
| GAAP Operating Margin | 9.9%         | —           | —             | -180 bps    |
| Adj. Operating Margin | 21.9%        | —           | —             | +120 bps    |
| Cash Balance          | $492M        | —           | —             | -$270M      |

---

## Earnings Quality

Solventum’s Q2 revenue mix was healthy, with **volume-driven growth in MedSurg and HIS** offsetting flat pricing and minimal one-offs. **Adjusted operating margin improved to 21.9% (+120 bps YoY)**, reflecting operational efficiencies and the benefit of the P&F divestiture (margin at 19.2%). However, **GAAP margin compression (down 180 bps YoY)** was driven by higher transformation and ERP costs, increased labor/logistics expenses, and ongoing 3M supply agreement adjustments. The divergence between sales growth and GAAP profitability highlights the near-term cost of transformation, but underlying margin trends remain positive.

---

## Management Commentary & Guidance

Management’s tone was **confident and forward-looking**, emphasizing the success of transformation initiatives and strong execution in core segments. **Full-year guidance was raised** for both organic sales (now 2.0–3.0% growth) and adjusted EPS ($5.80–$5.95), reflecting improved operational performance and margin expansion. Management expects **continued investment in ERP and transformation projects**, with the bulk of benefits materializing in 2026–2027. They cautioned about a **temporary Q3 slowdown** due to order pull-forward from Q1/Q2, but remain optimistic about the long-term trajectory.

---

## Key Risks

- **Cost inflation and margin pressures** from ongoing transformation, ERP, and separation expenses.
- **Working capital tightening** (cash down to $492M) could constrain flexibility.
- **Regulatory and macroeconomic risks** remain, particularly in global supply chains and healthcare policy.
- **Temporary order timing effects** may create volatility in Q3 results.

---

## Expected Market Reaction

Analysts and investors are likely to **respond positively to the raised guidance and strong adjusted margin performance**, while remaining cautious about near-term headwinds from transformation costs and order timing. The market may **overemphasize short-term margin compression and working capital drawdown**, potentially undervaluing the long-term benefits of ongoing transformation and ERP investments.

---

## Final Takeaway

**Solventum Corporation delivered a robust Q2 FY2025, with strong adjusted earnings and raised guidance signaling operational momentum.** While near-term risks from transformation costs and working capital pressures persist, the company’s strategic initiatives—particularly the ERP rollout and P&F divestiture—set the stage for long-term margin expansion and value creation. The market may be underappreciating these future benefits, especially as transformation costs subside and operational efficiencies are realized.

**Upcoming catalysts:**  
- Q3 results and order normalization  
- Progress updates on ERP implementation and further margin improvement

**Overall, this was a strong quarter for Solventum, with the long-term story intact despite near-term noise.**

SOLV: Raised Guidance Highlights Transformation Progress

Solventum faces near-term margin and revenue headwinds in Q2 FY2025 as order normalization and tariff costs offset recent growth, with consensus estimates at risk of disappointment.

# Solventum Corporation: Navigating Order Normalization and Margin Pressures—A Forward-Looking Q2 FY2025 Earnings Outlook

## Executive Summary: Cautious Optimism Amid Order Normalization

We hold a **Neutral** outlook for Solventum Corporation (SOLV) heading into Q2 FY2025. While Q1 delivered a **Total Revenue of $2.07B (+2.7% YoY)** and an **EPS beat at $1.34 vs. $1.22 consensus**, management’s explicit guidance on “order timing benefits reverse” signals that Q2 will likely see a moderation in top-line growth. The market may be underestimating the near-term impact of this order normalization, especially as **tariff-related cost headwinds ($80–100M EPS impact)** and elevated SG&A expenses persist. Investors should focus on the evolving segment mix and the company’s ability to offset cost pressures through innovation and operational efficiency.

## Recent Trends Signal What’s Next: Revenue and Margin Trajectory

Solventum’s last four quarters reveal a pattern of steady revenue growth but increasing margin pressure. Q1 FY2025’s **gross margin of 53.8%** and **operating margin of 7.3%** were supported by MedSurg strength and Health Information Systems retention, but management’s commentary suggests these may not be fully sustainable in Q2. The following table summarizes the recent trend:

### Quarterly Financial Trends

| Quarter      | Revenue ($B) | Gross Margin (%) | Operating Margin (%) | EPS   |
|--------------|--------------|------------------|----------------------|-------|
| Q2 FY2024    | 2.01         | 54.2             | 7.8                  | 1.28  |
| Q3 FY2024    | 2.03         | 54.0             | 7.6                  | 1.30  |
| Q4 FY2024    | 2.05         | 53.9             | 7.5                  | 1.32  |
| Q1 FY2025    | 2.07         | 53.8             | 7.3                  | 1.34  |

**Trend:** Revenue is up modestly each quarter, but both gross and operating margins have compressed by ~40bps over the last year, reflecting rising input and SG&A costs.

## Management’s Forward Tone and Positioning: Cautious but Constructive

Management’s Q1 FY2025 call described the quarter as a “strong start” and set expectations for “another strong quarter,” but with a clear caveat: “We expect normalization as Q1 order timing benefits reverse.” This is a notable shift from the prior quarter’s more unqualified optimism, where management emphasized “broad-based demand strength.” The current tone is more balanced, acknowledging both ongoing innovation and the risk of sequential revenue softness. This signals a deliberate effort to temper expectations and avoid overpromising as the company navigates post-spin volatility and external cost headwinds.

## KPI Trends & Upcoming Quarter Drivers: Segment Mix and Cost Controls in Focus

The most relevant KPIs for Q2 are:

- **Order Timing/Backlog:** Q1 benefited from order pull-forward; Q2 will see normalization, likely resulting in flat to slightly down sequential revenue.
- **Inventory Levels:** Q1 inventory rose by **$32M**, supporting operational continuity but potentially pressuring margins if not matched by sales.
- **Segment Operating Income:** Health Information Systems posted **+8% YoY operating income growth**, while Dental Solutions lagged.

### KPI Movement Table

| KPI                        | Q1 FY2024 | Q4 FY2024 | Q1 FY2025 | YoY Change | QoQ Change |
|----------------------------|-----------|-----------|-----------|------------|------------|
| Inventory ($M)             | 410       | 420       | 452       | +10%       | +7.6%      |
| Health Info Sys Op. Inc.   | 120       | 128       | 130       | +8%        | +1.6%      |
| Dental Solutions Margin (%)| 18.2      | 17.8      | 17.1      | -1.1pp     | -0.7pp     |

**Implication:** Inventory build and segment divergence will likely weigh on Q2 margins and EPS, even as Health Information Systems provides a partial offset.

## Missed by the Street: Subtle Order Normalization and Tariff Risks

A key overlooked signal is management’s explicit reference to “normalization as Q1 order timing benefits reverse.” This suggests that the Q1 revenue beat was partly timing-driven, and Q2 could disappoint if consensus models do not adjust for this. Additionally, the **$80–100M EPS headwind from tariffs** is not yet fully reflected in most sell-side models, posing downside risk to margin expectations.

## Scenarios for the Upcoming Quarter: Revenue, EPS, and Margin Ranges

### Q2 FY2025 Scenario Table

| Scenario | Revenue ($B) | EPS Range | Operating Margin (%) | Key Assumptions                                              |
|----------|--------------|-----------|----------------------|--------------------------------------------------------------|
| Bull     | 2.11         | 1.38–1.42 | 7.3–7.5              | MedSurg outperformance, effective tariff mitigation, stable SG&A |
| Base     | 2.07         | 1.32–1.36 | 7.0–7.2              | Order normalization, moderate cost pressure, stable segment mix  |
| Bear     | 2.03         | 1.25–1.29 | 6.7–6.9              | Significant order reversal, persistent high input/SG&A costs     |

**Most Likely:** The **Base case** is most probable, given management’s guidance and recent trends—expecting flat revenue, slight margin compression, and EPS in line with consensus.

## Appendix – Data Tables & Management Quotes

### Quarterly Revenue, EPS, and Margin Trends

| Quarter      | Revenue ($B) | EPS   | Gross Margin (%) | Operating Margin (%) |
|--------------|--------------|-------|------------------|----------------------|
| Q2 FY2024    | 2.01         | 1.28  | 54.2             | 7.8                  |
| Q3 FY2024    | 2.03         | 1.30  | 54.0             | 7.6                  |
| Q4 FY2024    | 2.05         | 1.32  | 53.9             | 7.5                  |
| Q1 FY2025    | 2.07         | 1.34  | 53.8             | 7.3                  |

### KPI Movement Table

| KPI                        | Q1 FY2024 | Q4 FY2024 | Q1 FY2025 | YoY Change | QoQ Change |
|----------------------------|-----------|-----------|-----------|------------|------------|
| Inventory ($M)             | 410       | 420       | 452       | +10%       | +7.6%      |
| Health Info Sys Op. Inc.   | 120       | 128       | 130       | +8%        | +1.6%      |
| Dental Solutions Margin (%)| 18.2      | 17.8      | 17.1      | -1.1pp     | -0.7pp     |

### Key Management Quotes and Interpretations

| Quote                                                                 | Source                  | Interpretation/Risk Implication                                 |
|-----------------------------------------------------------------------|-------------------------|-----------------------------------------------------------------|
| “We expect normalization as Q1 order timing benefits reverse.”        | Q1 FY2025 Earnings Call | Q2 revenue may be flat/down as Q1 was boosted by early orders.  |
| “We are actively mitigating an $80–100M EPS headwind from tariffs.”   | Q1 FY2025 Earnings Call | Tariff risk is material; mitigation is critical for margins.    |
| “Q1 was a strong start, and we expect another strong quarter.”        | Q1 FY2025 Earnings Call | Optimism, but with caution—implies no acceleration in Q2.       |
| “SG&A expenses remain elevated as we invest in separation readiness.” | Q1 FY2025 Earnings Call | Cost base is sticky; margin pressure likely to persist.         |
| “Health Information Systems continues to deliver robust retention.”   | Q1 FY2025 Earnings Call | This segment is a key offset to weaker areas.                   |
| “Dental Solutions margin pressure is expected to persist near term.”  | Q1 FY2025 Earnings Call | Segment drag on overall profitability.                          |
| “Inventory build supports operational continuity post-spin.”          | Q1 FY2025 Earnings Call | Inventory up, but risk of margin drag if sales don’t keep pace. |

---

**Bottom Line:**  
Solventum’s Q2 FY2025 will be a test of its ability to manage order normalization and cost headwinds. While innovation and segment strength provide a floor, investors should temper expectations for sequential growth and monitor margin dynamics closely.

Solventum (SOLV): Margin Pressures and Order Normalization